Blood marker helps predict early brain changes in MS

Credibility

Interest

Share:2 min read

Key Takeaway

Changes over time in a blood protein called neurofilament light (NfL) help predict new lesion activity and later brain shrinkage in early MS, even when MRI is considered.

What They Found

Researchers measured NfL, a protein released when nerve cells are injured, in blood samples and compared it to MRI scans and clinical outcomes. Higher NfL levels at the first test were linked to more lesions on MRI and a higher chance of being diagnosed with definite MS sooner. However, the one-time (baseline) NfL level stopped adding useful prediction when MRI and basic patient data were already known. When NfL levels were tracked over the first two years, rising or falling NfL matched later MRI signs of active disease (like new or changing lesions) and later brain shrinkage. In short, how NfL changes over time gave extra useful information about future brain changes that a single MRI snapshot did not fully show.

Who Should Care and Why

People with early MS or those who recently had a first episode (clinically isolated syndrome) may benefit, because regular blood NfL checks could help see if the disease is active even between MRIs. Caregivers can use this as another way to watch for changes that might need more doctor attention, like new symptoms or treatment review. Clinicians might use repeated NfL tests to decide if a treatment is working or if a stronger option is needed, similar to checking a car’s engine light more than once. For everyday life, knowing NfL is rising could prompt earlier discussions about symptom management, rehab, or safety at home. This finding gives patients another, less invasive tool (a blood test) that can add to MRI information when planning care.

Important Considerations

This study looked back at data from a specific early-treatment group, so results may not apply to every person with MS or to those on different treatments. A single NfL test was less helpful once MRI results were known, so blood tests are most useful when tracked over time, not as a one-off check. The study shows association (they move together) but does not prove changing NfL will always cause or fully predict every person’s symptoms or future course.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics MS Progression Early Research

Article Topics:

AtrophyLesionsMultiple sclerosisNeurofilamentProgression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News